Background-Transradial percutaneous coronary intervention (PCI [TRI
A cute kidney injury (AKI) is a common complication of percutaneous coronary interventions (PCI) and is associated with increased morbidity and mortality.
1-3 AKI after PCI is commonly referred to as contrast-induced nephropathy, suggesting that use of iodinated contrast media is the major cause of acute kidney injury after PCI. Although contrast media certainly play an important role in the development of AKI after PCI, other pathogeneses such as hemodynamic instability and cholesterol embolization might also have an impact on its occurrence. Angiography is responsible for 80% of the iatrogenic cases of renal cholesterol embolization, and 0.06% to 1.8% of patients undergoing coronary angiography develop this complication. [4] [5] [6] [7] Therefore, although the main focus for prevention of AKI after PCI lies on intravenous volume expansion and minimization of contrast volume, 8, 9 the route of vascular access for PCI might also play a role.
Femoral vascular access is the most commonly used strategy to perform PCI in the United States, [10] [11] [12] [13] although frequency of radial access is increasing.
14 Transradial PCI (TRI) is associated with a reduction in vascular complications and bleeding, 15 and may thereby reduce the risk of renal injury from hemodynamic instability resulting from hemorrhagic complications. 16 Second, the risk of cholesterol embolization to the kidney may be minimized by avoiding catheterization of the descending aorta. It is possible that, by these mechanisms, the risk of AKI might be lower in patients undergoing TRI compared with transfemoral PCI (TFI). However, this hypothesis has not been tested in any large contemporary study. Hence, we compared the risks of AKI and nephropathy requiring dialysis (NRD) between patients in whom PCI was performed by TRI versus TFI among a large population undergoing contemporary PCI in Michigan.
Methods
This study was performed using data from the Blue Cross Blue Shield of Michigan cardiovascular consortium (BMC2), a regional registry of patients undergoing PCI. A detailed description of the BMC2 registry has previously been described. [17] [18] [19] Briefly, consecutive patients undergoing PCI at the 47 participating centers were included. Data on route of vascular access, study outcomes, medication, laboratory values, and procedural and demographic patient characteristics were collected using standardized data collection forms. All collected variables have been prospectively defined, and a random audit in 2% of included patients was performed to ensure data accuracy. We excluded patients on dialysis before PCI, or those with incomplete data on serum creatinine levels before or after PCI, or those who died in the catheterization laboratory. Participation in the registry has either been approved or the need for approval was waived by local institutional review boards of all participating hospitals because the registry is part of each sites' quality improvement program.
For this current study, consecutive patients undergoing emergent or elective TRI or TFI between 2010 and 2012 were included. Preprocedural serum creatinine values were measured within 30 days before PCI, with a preference for the value closest to the time of PCI. Peak postprocedural creatinine was the highest creatinine value obtained within 1 to 7 days of the procedure or the highest value in the first 30 days of hospitalization and was ascertained per institutional practice. Type of contrast media and the use AKI preventive measures were according to standard clinical practice in the participating hospitals. The use of TRI or TFI was according to operator preference.
Study End Points
The primary end point of this study was the occurrence of AKI. AKI was defined by an absolute increase in serum creatinine ≥0.5 mg/dL because this definition was found to be preferable compared with the alternative AKI definition of a relative creatinine increase >25% in patients undergoing PCI. 20 Secondary end points were the occurrence of NRD, postprocedural bleeding, and in-hospital mortality. NRD was defined as new unplanned need for dialysis after PCI during the same hospitalization. Postprocedural bleeding was defined as bleeding within 72 hours after PCI causing a drop in hematocrit >10% and a drop in hemoglobin levels ≥3 g/dL, or requiring transfusion of ≥1 unit of whole blood.
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Statistical Analyses
Continuous variables were expressed as means with standard deviations, and categorical variables were expressed as counts with
WhAT IS KNOWN
• Transradial percutaneous coronary intervention (PCI) is associated with a reduction in vascular complications and bleeding, and may thereby reduce the risk of renal injury from hemodynamic instability resulting from hemorrhagic complications.
• The risk of cholesterol embolization to the kidney may be minimized by the use of transradial PCI avoiding catheterization of the descending aorta, which may also reduce the risk of renal complications after PCI.
WhAT ThE STUDy ADDS
• This study demonstrates the risk of acute kidney injury to be significantly lower after transradial compared with transfemoral PCI.
• Although our study lacked statistical power to demonstrate a significant difference in the rare occurrence of nephropathy requiring dialysis after PCI between both groups, a trend toward a protective effect of transradial PCI was noted in the unadjusted analysis. percentages. Association between access site and baseline covariates was assessed using t tests for continuous variables and χ 2 tests for categorical variables. The estimated associations between access site and study outcomes were reported as odds ratios (OR) and assessed univariately using Fisher exact test and multivariately using logistic regression models to adjust for baseline estimated glomerular filtration rate (eGFR) calculated using the Simplified Modification of Diet in Renal Disease formula, 22 all covariates included in the propensity-matching score (Table 1) , and the patients preprocedural estimated risk of AKI as established by a risk tool using baseline clinical characteristics. 23 Propensity matching was used to address differences in patient characteristics at baseline between patients in the TRI and TFI groups by constructing a subset of patients balanced on these characteristics. A propensity score was developed from a logistic regression model with access site as the outcome and including baseline patient demographic and clinical characteristics as predictors (Table 1) . Patients with TRI and TFI were matched without replacement on a 1:1 basis using a nearest neighbor (greedy) algorithm, 24, 25 and requiring exact matching on the year and quarter (January-March, April-June, July-September, October-December) of hospital discharge. To assess the adequacy of matching and covariate balance between the 2 groups, we examined the standardized differences for the included baseline covariates in the matched cohort.
In addition to the overall matched cohort, patients with TRI and TFI were also independently matched using the same propensity score with the addition of exact matching on a number of subgroups defined by baseline clinical characteristics detailed below.
Subgroup analyses on all study outcomes were performed for elective versus patients with urgent PCI, by category of preexisting chronic kidney disease (eGFR ≤30, 30-60, and >60 mL/min), age (≤70 versus >70 years), patients with an ST-elevation myocardial infarction (STEMI), patients with non-ST-elevation myocardial infarction (NSTEMI), and patients in cardiogenic shock.
We aimed to explore whether observed associations between the risk of AKI and access site could be explained through the impact of expected decreases in bleeding events with TRI. Therefore, logistic regression models were used in the propensity-matched cohort to adjust for bleeding as a potential intermediary mechanism (see Appendix in the Data Supplement). 26 A sensitivity analysis was performed to examine the robustness of the results, particularly the primary outcome of AKI, to unmeasured confounders. 27 This analysis evaluated the extent to which an unknown confounding factor associated with both an outcome of interest and the choice of vascular access site might be responsible for a statistically significant result detected in our analysis where no true association existed. We evaluated the impact on our results of this assumed confounder under 12 scenarios reflecting either a moderate (OR, 1.5) or strong (OR, 3.0) association with the outcome and a range of differential prevalence in patients with TRI and TFI.
A post hoc sensitivity analysis was also performed to assess the potential for hospital-level variability to impact our results. Hierarchical generalized linear mixed effects regression models were fitted to the full data set for the outcomes of AKI and bleeding, incorporating a normally distributed hospital random effect in addition to all covariates included in the base models. The R lme4 package was used for this analysis. 28 A nominal significance level of 0.05 was used for statistical analyses without adjustment for multiple comparisons because such statements of statistical significance and reported P values should be interpreted as hypothesis generating rather than confirmatory evidence.
Results
In total 96 753 PCI procedures were performed across Michigan between January 1, 2010, and December 31, 2012. Of those, 2251 procedures were excluded because patients were already on dialysis; 11 997 procedures were excluded because of missing serum creatinine values before and after PCI; and 404 procedures were excluded because of use of brachial access. As a result, the total study population consisted of 80 359 patients undergoing 82 225 PCI procedures, of which 8915 (10.8%) procedures were TRI and 73 310 TFI (Figure 1 ). There were no hospitals where all patients underwent TRI; however, in 6 hospitals, TFI was used exclusively. In all other hospitals, both routes of vascular access were used for PCI.
Patient characteristics at baseline, categorized by access site, are reported in Table 2 . Compared with patients in the TFI group, patients in whom TRI was performed were more likely to have a history of hypertension, dyslipidemia, and diabetes mellitus, whereas patients with TFI were more likely to have a history of previous myocardial infarction, cerebrovascular or peripheral artery disease, and to present with heart failure, cardiogenic shock, cardiac arrest, or with STEMI. Mean contrast volumes used at time of PCI were 189.4 mL (SD 78.1) for TRI and 191.7 mL (SD 78.1) for TFI (P<0.001). The propensitymatched population consisted of 17 714 procedures, with 8857 procedures in both TRI and TFI groups. After matching, the groups were generally similar in terms of clinical and demographic patient characteristics at baseline (Table 3) . Median duration of hospital stay in patients who were discharged alive within the entire and the propensity-matched population was similar for patients treated with TRI and TFI (median duration for both groups 2 days, interquartile range 1-3 days). Table 4 provides incidences of study outcomes for the total population and the propensity-matched cohort, along with crude OR estimates and estimates after adjusting for predicted AKI risk. Overall crude event rates for all 4 outcomes studied were significantly lower for patients treated via TRI compared with TFI within the total population. After adjustment for baseline covariates in multivariate regression models, the radial approach remained significantly associated with lower risks of AKI (OR, 0.76; 95% confidence intervals Data are presented as mean, standard deviation or n, %. Abs std diff indicates absolute standard difference between the 2 groups; CABG, coronary artery bypass graft; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; NSTEMI, non-(STEMI) ST-elevation MI; and PCI, percutaneous coronary intervention. Figure 2 provides estimated crude ORs and confidence intervals for propensity-matched patients by subgroup. As confidence intervals generally overlap, the results do not strongly suggest heterogeneity of effect across subgroups.
Study Outcomes
To explore whether the lower risk of AKI after TRI was mediated by the lower risk of bleeding observed in that patient group, logistic regression models were used in the propensity-matched cohort to adjust for bleeding as a potential intermediary mechanism. After adjusting for postprocedural bleeding along with baseline preprocedural characteristics, the TRI versus TFI OR for AKI was 0.76 (P=0. Sensitivity analysis (Table 5) demonstrates that the observed association between access site and AKI incidence could potentially be explained by a moderately strong unknown confounder (scenarios 5, 6, and 9-12), whereas the observed bleeding association is large enough to be robust (in terms of significance) under the scenarios evaluated.
Discussion
The key finding of our study is that TRI was associated with a significantly reduced risk of AKI compared with TFI, after adjustment for confounding by propensity matching and preprocedural calculated risk of AKI. Mediation analysis did not suggest that this association was the result of the lower risk of PCI-related bleeding in the TRI group.
Our study findings significantly extend previous work in this field as the first study to analyze the risk of AKI after TRI Odds ratios of acute kidney injury (AKI), bleeding, and in-hospital mortality were adjusted for admission date, quarter of discharge (YYYYQQ), percutaneous coronary intervention (PCI) indication, heart failure within 2 wk, sex, cardiomyopathy or left ventricular systolic dysfunction, use of intra-aortic balloon pump, preoperative evaluation before noncardiac surgery, hypertension, cardiogenic shock within 24 h, dyslipidemia, cardiac arrest within 24 h, body mass index, stress or imaging studies performed, previous myocardial infarction, coronary artery disease presentation, previous heart failure, diagnostic left heart catheterization or diagnostic coronary angiography, previous valve surgery/procedure, other procedure (in conjunction with diagnostic catheterization or PCI), previous PCI, current/recent smoker (within 1 y), previous coronary artery bypass graft, other mechanical ventricular support, height, weight, undocumented closure method, cardiogenic shock at start of PCI, cerebrovascular disease, antianginal medication within 2 wk, peripheral arterial disease, estimated glomerular filtration rate, chronic lung disease, and family history of premature coronary artery disease. CI indicates confidence intervals; NRD, nephropathy requiring dialysis; OR, odds ratio; PCI, percutaneous coronary intervention; TFI, transfemoral PCI; and TRI, transradial PCI.
*The odds ratio of nephropathy requiring dialysis was adjusted only for baseline-predicted risk and estimated glomerular filtration rate because of small number of events. Data are presented as mean, standard deviation or n, %. Abs std diff indicates absolute standard difference between the 2 groups; CABG, coronary artery bypass graft; CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; NSTEMI, non-(STEMI) ST−elevation MI; and PCI, percutaneous coronary intervention. 29 Because other advantages of TRI are being recognized, our findings add further to the evidence base and are indicative of a preference for the use of this approach.
Our study findings suggest the risk of AKI to be significantly lower after TRI compared with TFI. The only previous study on this subject analyzed the risk of new onset or progression of chronic kidney disease within 6 months after PCI comparing TRI with TFI. 30 Although the study did not report on the risk of AKI, it demonstrated that the risk of new onset or progression of chronic kidney disease was lower after TRI compared with TFI. Second, that study concluded that the risk of NRD was also lower after TRI. Although our study lacked statistical power to demonstrate a significant difference in the rare occurrence of NRD after PCI between both groups, a trend toward a protective effect of TRI was noted in the unadjusted analysis. AKI after PCI is a multicausal phenomenon induced by nephrotoxic effects of iodinated contrast media, changes in hemodynamics, and cholesterol embolization into the renal vasculature. In clinical practice, it is difficult to make a distinction between these different pathogenes. One or more of these factors may explain why there is a lower risk of renal complications after TRI. First, TRI might minimize the risk of cholesterol embolization to the kidney. Second, as has been demonstrated by other studies, contrast volumes used for PCI were lower for TRI compared with TFI, although this difference was modest and probably not clinically relevant. 30 Finally, it is possible that there was a reduction in episodes of hypotension because of hemodynamically significant bleeding or vaso vagal responses in association with femoral sheath removal with resultant component of ischemic renal injury. Our study is unable to account for these differences.
The risk of bleeding was significantly lower in the TRI group. This result is consistent with outcomes of previous observational studies analyzing clinical outcomes after PCI. [31] [32] [33] This finding was robust in all our analyses and seemed to be extant in sensitivity analysis demonstrating the pre-eminence of TRI for reducing bleeding complications. Recently, a strong association between bleeding and AKI was demonstrated in patients undergoing PCI. 16 Although we were able to corroborate this finding, the observed reduction in bleeding with TRI did not seem to mediate the reduction in AKI observed in our study.
The results of our study must be interpreted with certain caveats. First of all, we performed an observation study, where hospital guidelines and the preference of the operator influenced the choice for the route of vascular access. We adjusted for this by the use of propensity matching and a sophisticated risk adjustment model. However, residual confounding might still be present in the analyses on the risk of AKI comparing TRI with TFI. Indeed, our sensitivity analysis suggests that the presence of a strong unmeasured confounder would negate the observed differences in AKI. Thus, our findings should be considered hypothesis generating and require confirmation in randomized controlled trials before any changes in clinical practice can be recommended. Second, the type of contrast media and the use of AKI preventive treatments were according to clinical practice and not standardized. However, this also makes our results more generalizable to daily practice. Third, information on the need for other contrast studies or surgery after PCI was unavailable. Nonetheless, the need for such procedures is among others determined by the presence of comorbidity and a patient's presentation at the time of PCI. Because these possible confounders are taken into the propensity score, it is unlikely that there would be a clinically significant difference in the need for other contrast studies or surgery between the TRI and TFI group within the propensity-matched population. Fourth, we were unable to study differences in trajectory of creatinine increases comparing TRI with TFI.
In conclusion, the results in our clinical practice study suggest that the risk of AKI is potentially lower after TRI compared with TFI. The use of TRI is associated with a significant reduction in bleeding events. Although these data suggest an additional clinical advantage of TRI, this finding needs to be explored in randomized controlled trials.
